Dualsystems Biotech closes Series C Financing Round

Please login or
register
30.09.2013

Dualsystems has closed a Series C financing round with support from existing and new investors to implement and drive forward its new business strategy in mass spectrometry based protein interaction discovery.

Following the recently announced licensing of a new technology to provide mass-spectrometry based target- and protein-interaction discovery services from the ETH Zurich and the sale of its former yeast-based technologies business, Dualsystems Biotech now has successfully raised additional funds from existing and new investors.

“This is the third and consequential step in the transition process of Dualsystems Biotech during which we have moved from the previous yeast-based techniques towards a portfolio of highly innovative mass-spectrometry based services for target interaction discovery. These new services will be provided to the life sciences industry as well as to academic groups”, Andreas J. Schulze, CEO, says.

About Dualsystems Biotech AG
Dualsystems Biotech is a Swiss biotech company founded in 2000. Dualsystems successfully introduced yeast 2-hybrid technologies to the market and has been the leader in broadening its fields of application. In recent years the mass spectrometry-based proteomics technologies have become a major pillar of the company’s expertise. The company now exclusively focuses on its mass spectrometry-based CaptiVate and CaptiRec technologies. During two financing rounds in 2000 and in 2007 Dualsystems Biotech has built a solid investor base including private individuals as well as institutional investors to support our technology driven growth strategy.

0Comments

More news about

Dualsystems Biotech AG

Company profiles on startup.ch

Dualsystems Biotech AG

rss